Jonathan Thomas, PhD, JD, is President and CEO of the California Institute for Regenerative Medicine (CIRM). Thomas was previously the Chair of the CIRM governing Board from June 2011 to March 2023.

The simple term “stem cell” actually refers to many different types of cells. The tissue-specific stem cells, or adult stem cells, replenish tissues throughout our lives. Embryonic stem cells exist ...

Anne-Marrie Duliege, MD, is a Senior Executive and Chief Medical Officer with 30 years of experience guiding biopharmaceutical companies through development and commercial stages. Dr. Duliege is ...

The last thing Maria Torres expected was to be diagnosed with type 2 diabetes. She exercised, ate well and kept her weight under control. There had to be some mistake. Maria asked her doctor to repeat ...

CIRM is governed by 35 dedicated Californians representing patients, researchers and the biotechnology industry whose knowledge, passion and commitment to CIRM’s mission has guided the organization ...

https://im.csgsystems.com/cgi-bin/confCast Enter Conference ID# 457698 Then click Go. 3. Discussion of Personnel [Evaluation of President] (Government Code section ...

If you would like to contact CIRM regarding questions you may have about employment opportunities, please contact us at [email protected]. CIRM encourages job seekers to apply for specific job openings ...

San Francisco, CA – California’s stem cell agency, the California Institute for Regenerative Medicine (CIRM) today approved $150 million in new funding to help move promising stem cell-based therapies ...

Les membres du public qui écoutent la réunion et souhaitent faire un commentaire auront la possibilité de le faire en procédant comme suit : Une fois que nous aurons lancé un appel aux commentaires du ...

CIRM has one singular mission: Accelerating world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world. A dedication to ...

Currently, CIRM is not accepting new applications for any existing Clinical (CLIN), Translational (TRAN), Education (EDUC), or Infrastructure (INFR) opportunities. However, CIRM will accept ...

Researchers at the California Institute for Biomedical Research (CALIBR) have been awarded $8.447 million to test KA34, a drug that, in preclinical tests, recruits stem cells to create new cartilage ...